The microbiome restrains melanoma bone growth by promoting intestinal NK and Th1 cell homing to bone.
Bone Biology
Melanoma
Journal
The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877
Informations de publication
Date de publication:
15 06 2022
15 06 2022
Historique:
received:
07
12
2021
accepted:
29
04
2022
pubmed:
4
5
2022
medline:
18
6
2022
entrez:
3
5
2022
Statut:
ppublish
Résumé
Bone metastases are frequent complications of malignant melanoma leading to reduced quality of life and significant morbidity. Regulation of immune cells by the gut microbiome influences cancer progression, but the role of the microbiome in tumor growth in bone is unknown. Using intracardiac or intratibial injections of B16-F10 melanoma cells into mice, we showed that gut microbiome depletion by broad-spectrum antibiotics accelerated intraosseous tumor growth and osteolysis. Microbiome depletion blunted melanoma-induced expansion of intestinal NK cells and Th1 cells and their migration from the gut to tumor-bearing bones. Demonstrating the functional relevance of immune cell trafficking from the gut to the bone marrow (BM) in bone metastasis, blockade of S1P-mediated intestinal egress of NK and Th1 cells, or inhibition of their CXCR3/CXCL9-mediated influx into the BM, prevented the expansion of BM NK and Th1 cells and accelerated tumor growth and osteolysis. Using a mouse model, this study revealed mechanisms of microbiota-mediated gut-bone crosstalk that are relevant to the immunological restraint of melanoma metastasis and tumor growth in bone. Microbiome modifications induced by antibiotics might have negative clinical consequences in patients with melanoma.
Identifiants
pubmed: 35503658
pii: 157340
doi: 10.1172/JCI157340
pmc: PMC9197523
doi:
pii:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK112946
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR028009
Pays : United States
Organisme : NIA NIH HHS
ID : U54 AG062334
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA270030
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM072808
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR066551
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM104323
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK119229
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK124821
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM095442
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR079298
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR068157
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR070091
Pays : United States
Organisme : BLRD VA
ID : I01 BX000105
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA235096
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Nat Commun. 2020 Jan 24;11(1):468
pubmed: 31980603
PLoS One. 2013 Nov 06;8(11):e79939
pubmed: 24223204
Biomed Res Int. 2014;2014:413982
pubmed: 25197644
J Vis Exp. 2012 Sep 04;(67):e4260
pubmed: 22972196
For Immunopathol Dis Therap. 2016;7(1-2):41-55
pubmed: 28616355
Proc Natl Acad Sci U S A. 2014 May 6;111(18):6696-701
pubmed: 24753589
J Exp Med. 1981 Mar 1;153(3):569-82
pubmed: 6166701
J Immunol. 1993 Sep 1;151(5):2511-20
pubmed: 8103068
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
pubmed: 9636188
Cell Mol Immunol. 2020 Jan;17(1):1-12
pubmed: 31611651
PeerJ. 2017 Jun 15;5:e3450
pubmed: 28630804
Comput Methods Biomech Biomed Engin. 1997;1(1):15-23
pubmed: 11264794
Cell Metab. 2015 Nov 3;22(5):799-810
pubmed: 26456334
Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101
pubmed: 20061941
J Immunol. 2001 Feb 15;166(4):2276-82
pubmed: 11160282
ACS Med Chem Lett. 2013 Jan 04;4(3):333-7
pubmed: 24900670
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14205-10
pubmed: 14612570
J Bone Miner Res. 2014 Jan;29(1):43-54
pubmed: 24357520
J Invest Dermatol. 2006 Jan;126(1):32-41
pubmed: 16417215
Cancer Res. 2008 Oct 15;68(20):8437-45
pubmed: 18922917
J Bone Miner Res. 2018 Dec;33(12):2099-2113
pubmed: 30476357
Immunol Rev. 1997 Jun;157:177-94
pubmed: 9255630
Trends Immunol. 2015 Jan;36(1):49-58
pubmed: 25432489
J Bone Miner Res. 2016 Sep;31(9):1638-46
pubmed: 27317164
Cancer Res. 2003 Aug 15;63(16):4763-5
pubmed: 12941790
Nat Rev Microbiol. 2013 Apr;11(4):227-38
pubmed: 23435359
Nature. 2012 Nov 8;491(7423):254-8
pubmed: 23034650
Int Immunopharmacol. 2018 Oct;63:66-73
pubmed: 30075430
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Apoptosis. 2003 Jun;8(3):237-49
pubmed: 12766484
J Bone Miner Res. 2017 Jun;32(6):1343-1353
pubmed: 28244143
Trends Immunol. 2015 Dec;36(12):778-787
pubmed: 26596799
Cell. 2021 Oct 14;184(21):5338-5356.e21
pubmed: 34624222
J Pathol. 2008 Jan;214(2):179-89
pubmed: 18161751
Clin Cancer Res. 2002 Mar;8(3):922-31
pubmed: 11895927
Exp Ther Med. 2019 Dec;18(6):4845-4851
pubmed: 31772648
J Clin Invest. 2020 Apr 1;130(4):1767-1781
pubmed: 31917685
J Bone Miner Res. 1999 Jul;14(7):1167-74
pubmed: 10404017
Cancer Res. 2019 Dec 1;79(23):5999-6009
pubmed: 31591154
Exp Cell Res. 2011 Mar 10;317(5):620-31
pubmed: 21376175
Immunity. 2019 Jun 18;50(6):1498-1512.e5
pubmed: 31097342
Science. 1977 Aug 26;197(4306):893-5
pubmed: 887927
Gut Microbes. 2020 Jul 3;11(4):1030-1042
pubmed: 32240032
Br J Pharmacol. 2012 Nov;167(5):1035-47
pubmed: 22646698
Nat Rev Cancer. 2002 Nov;2(11):850-61
pubmed: 12415255
Eur J Immunol. 2006 Sep;36(9):2394-400
pubmed: 16917961
J Bone Miner Res. 2020 Apr;35(4):801-820
pubmed: 31886921
J Clin Invest. 2021 Feb 15;131(4):
pubmed: 33586672
Cell. 2004 Jul 23;118(2):229-41
pubmed: 15260992
J Oncol. 2012;2012:647684
pubmed: 22792102
Neural Regen Res. 2019 Nov;14(11):1950-1960
pubmed: 31290453
J Bone Miner Res. 2010 Jul;25(7):1468-86
pubmed: 20533309
Bone. 2018 Oct;115:59-67
pubmed: 28433758
Bone. 2007 Oct;41(4):505-15
pubmed: 17693147
J Clin Invest. 2010 Mar;120(3):883-93
pubmed: 20179354
Cell. 2017 Jul 27;170(3):548-563.e16
pubmed: 28753429
Int J Mol Sci. 2021 Jul 27;22(15):
pubmed: 34360802
Science. 1996 May 3;272(5262):719-22
pubmed: 8614832
Nat Med. 2016 May;22(5):516-23
pubmed: 27019327
iScience. 2021 Aug 20;24(9):103012
pubmed: 34522855
Nat Immunol. 2007 Dec;8(12):1337-44
pubmed: 17965716
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10871-6
pubmed: 18663225
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):356-365
pubmed: 28270698
J Biomed Biotechnol. 2011;2011:473097
pubmed: 21660136
J Invest Dermatol. 2005 Jul;125(1):159-165
pubmed: 15982316
J Bone Miner Res. 2015 Apr;30(4):695-705
pubmed: 25359628
Cancer J. 2015 Jul-Aug;21(4):343-50
pubmed: 26222088
J Leukoc Biol. 2016 Nov;100(5):865-879
pubmed: 27605211
Immunity. 2016 Nov 15;45(5):1078-1092
pubmed: 27851911
Immunol Rev. 2007 Dec;220:169-82
pubmed: 17979846
Cancer Immunol Immunother. 2015 Feb;64(2):225-35
pubmed: 25344904
Elife. 2021 Jan 12;10:
pubmed: 33432923
Oncoimmunology. 2016 Sep 20;5(12):e1235106
pubmed: 28151533
Cancer Res. 2019 Jul 15;79(14):3662-3675
pubmed: 31064848
Transplant Proc. 2001 Feb-Mar;33(1-2):530-1
pubmed: 11266942
J Immunol. 2000 Nov 15;165(10):5495-501
pubmed: 11067902
Int J Med Microbiol. 2010 Jan;300(1):11-8
pubmed: 19781991
Cell. 2014 May 8;157(4):776-83
pubmed: 24813605
Nat Rev Immunol. 2006 Dec;6(12):940-52
pubmed: 17124515
J Clin Invest. 2016 Jun 1;126(6):2049-63
pubmed: 27111232
Science. 2013 Nov 22;342(6161):967-70
pubmed: 24264989